Motzer RJ, Penkov K, Haanen JBAG, et al. JAVELIN Renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC). ESMO 2018, abstract LBA6_PR.
Combinatie JAK-remmer en anti-PD-1 bij gemetastaseerd NSCLC
sep 2024 | Immuuntherapie, Longoncologie